Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events

Alena Y. Khromava, Rachel Barwick Eidex, Leisa H. Weld, Katrin S. Kohl, Robert D. Bradshaw, Robert T. Chen, Martin S. Cetron, Elisabeth Barnett, Rachel Barwick, Adwoa Bentsi-Enchill, Robert D. Bradshaw, Scott Campbell, Christine Casey, Martin Cetron, Frank Destefano, Philippe Duclos, Anna Durbin, Roseanne English-Bullard, Mark Feinberg, John IskanderAlena Khromava, Katrin Kohl, Anthony Marfin, Lewis Markoff, Ann McMahon, Elaine Miller, Susan Montgomery, Drew Posey, Michelle Russell, James Sejvar, Sean Shadomy, Mary Wilson, Sherif Zaki, Thomas Monath, Dirk Teuwen

Research output: Contribution to journalArticle

Abstract

Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990-2002, we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting rates of serious adverse events were significantly higher among vaccinees aged ≥60 years than among those 19-29 years of age (reporting rate ratio = 5.9, 95% CI 1.6-22.2). Yellow fever is a serious and potentially fatal disease. For elderly travelers, the risk for severe illness and death due to yellow fever infection should be balanced against the risk of a serious adverse event due to YEL.

Original languageEnglish (US)
Pages (from-to)3256-3263
Number of pages8
JournalVaccine
Volume23
Issue number25
DOIs
StatePublished - May 9 2005

    Fingerprint

Keywords

  • Adverse drug reaction reporting systems
  • Age groups
  • Vaccination/adverse effects
  • Yellow fever vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Khromava, A. Y., Eidex, R. B., Weld, L. H., Kohl, K. S., Bradshaw, R. D., Chen, R. T., Cetron, M. S., Barnett, E., Barwick, R., Bentsi-Enchill, A., Bradshaw, R. D., Campbell, S., Casey, C., Cetron, M., Destefano, F., Duclos, P., Durbin, A., English-Bullard, R., Feinberg, M., ... Teuwen, D. (2005). Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events. Vaccine, 23(25), 3256-3263. https://doi.org/10.1016/j.vaccine.2005.01.089